DE69837324T2 - Behandlung der multiplen sklerose durch einnahme von copolymer-1 - Google Patents

Behandlung der multiplen sklerose durch einnahme von copolymer-1 Download PDF

Info

Publication number
DE69837324T2
DE69837324T2 DE69837324T DE69837324T DE69837324T2 DE 69837324 T2 DE69837324 T2 DE 69837324T2 DE 69837324 T DE69837324 T DE 69837324T DE 69837324 T DE69837324 T DE 69837324T DE 69837324 T2 DE69837324 T2 DE 69837324T2
Authority
DE
Germany
Prior art keywords
glatiramer acetate
eae
cells
enteric
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69837324T
Other languages
German (de)
English (en)
Other versions
DE69837324D1 (de
Inventor
Ruth Arnon
Michael Sela
Dvora Teitelbaum
Adrian Gilbert
Milka Linenberg
Rivka Riven-Kreitman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd
Application granted granted Critical
Publication of DE69837324D1 publication Critical patent/DE69837324D1/de
Publication of DE69837324T2 publication Critical patent/DE69837324T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Treatments Of Macromolecular Shaped Articles (AREA)
  • Peptides Or Proteins (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
DE69837324T 1997-01-10 1998-01-12 Behandlung der multiplen sklerose durch einnahme von copolymer-1 Expired - Lifetime DE69837324T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL11998997 1997-01-10
IL11998997A IL119989A0 (en) 1997-01-10 1997-01-10 Pharmaceutical compositions for oral treatment of multiple sclerosis
PCT/US1998/000375 WO1998030227A1 (en) 1997-01-10 1998-01-12 Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1

Publications (2)

Publication Number Publication Date
DE69837324D1 DE69837324D1 (de) 2007-04-26
DE69837324T2 true DE69837324T2 (de) 2007-11-29

Family

ID=11069682

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69837324T Expired - Lifetime DE69837324T2 (de) 1997-01-10 1998-01-12 Behandlung der multiplen sklerose durch einnahme von copolymer-1

Country Status (18)

Country Link
EP (1) EP0975351B1 (cg-RX-API-DMAC7.html)
JP (1) JP4216342B2 (cg-RX-API-DMAC7.html)
KR (1) KR20000070058A (cg-RX-API-DMAC7.html)
CN (1) CN100528222C (cg-RX-API-DMAC7.html)
AT (1) ATE356608T1 (cg-RX-API-DMAC7.html)
AU (1) AU737287B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI9807076B8 (cg-RX-API-DMAC7.html)
CA (1) CA2277365C (cg-RX-API-DMAC7.html)
CZ (1) CZ297983B6 (cg-RX-API-DMAC7.html)
DE (1) DE69837324T2 (cg-RX-API-DMAC7.html)
EA (1) EA003128B1 (cg-RX-API-DMAC7.html)
HU (1) HU226612B1 (cg-RX-API-DMAC7.html)
IL (2) IL119989A0 (cg-RX-API-DMAC7.html)
NZ (1) NZ336690A (cg-RX-API-DMAC7.html)
PL (1) PL193300B1 (cg-RX-API-DMAC7.html)
SK (1) SK284029B6 (cg-RX-API-DMAC7.html)
WO (1) WO1998030227A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA98214B (cg-RX-API-DMAC7.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003521448A (ja) * 1998-07-23 2003-07-15 ザ・プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ 合成ペプチドおよび自己免疫疾患治療のための使用方法
EP1098902A4 (en) 1998-07-23 2002-07-24 Yeda Res & Dev TREATMENT OF AUTOIMMUNE DISEASES WITH COPOLYMER 1 AND RELATED COPOLYMERS AND PEPTIDES
ES2527760T3 (es) 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
US6800287B2 (en) 1998-09-25 2004-10-05 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
US6872739B1 (en) * 1999-06-04 2005-03-29 Vereniging Voor Christelijk Wetenshappelikjk Onderwijs Use of riluzole for the treatment of multiple sclerosis
CA2375874A1 (en) * 1999-06-04 2000-12-14 Chris Polman Use of riluzole for the treatment of multiple sclerosis
MXPA02008023A (es) * 2000-02-18 2005-06-30 Yeda Res & Dev Formulaciones de copolimero 1 para dosificacion oral, nasal y pulmonar.
US7022663B2 (en) 2000-02-18 2006-04-04 Yeda Research And Development Co., Ltd. Oral, nasal and pulmonary dosage formulations of copolymer 1
US20020077278A1 (en) 2000-06-05 2002-06-20 Yong V. Wee Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
CA2411536A1 (en) * 2000-06-05 2001-12-13 V. Wee Yong The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
WO2002076503A1 (en) 2000-06-20 2002-10-03 Mayo Foundation For Medical Education And Research Treatment of central nervous system diseases by antibodies against glatiramer acetate
EP1459065B1 (en) 2001-12-04 2010-07-28 Teva Pharmaceutical Industries, Ltd. Processes for the measurement of the potency of glatiramer acetate
KR20040105740A (ko) 2002-02-25 2004-12-16 엘란 파마슈티칼스, 인크. 염증 치료제의 투여 방법
JP2007521249A (ja) * 2003-01-24 2007-08-02 エラン ファーマシューティカルズ,インコーポレイテッド 脱髄疾患および麻痺のための組成物ならびに再有髄化剤を投与することによるそれらの治療
HRP20160455T1 (hr) 2004-09-09 2016-07-15 Yeda Research And Development Co., Ltd. Smjese polipeptida, sastavi koji ih sadrže i postupci za njihovu pripremu, te njihove primjene
RS55607B1 (sr) 2009-08-20 2017-06-30 Yeda Research & Development Company Ltd Niskofrekventna terapija glatiramer acetatom
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8759302B2 (en) 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
EA025780B1 (ru) 2010-10-11 2017-01-30 Тева Фармасьютикал Индастриз Лтд. Цитокиновые биомаркеры в качестве биомаркеров, прогнозирующих клинический ответ на глатирамер ацетат
MX2014004309A (es) 2011-10-10 2015-07-06 Teva Pharma Polimorfismos de nucleotidos individuales utiles para predecir una respuesta clinica para el acetato de glatiramer.
WO2014058976A2 (en) 2012-10-10 2014-04-17 Teva Pharmaceutical Industries Ltd. Biomarkers predictive for clinical response for glatiramer acetate
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
CN105884866B (zh) * 2015-01-26 2021-04-20 漳州未名博欣生物医药有限公司 格拉替雷的化学合成方法
US9155775B1 (en) 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product
CN112649537B (zh) * 2015-04-28 2024-03-29 深圳翰宇药业股份有限公司 多肽混合物高效液相色谱分析方法
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
AU2017319728B2 (en) 2016-08-31 2024-09-05 Mapi Pharma Ltd Depot systems comprising glatiramer acetate
IL316573A (en) 2017-03-26 2024-12-01 Mapi Pharma Ltd Storage systems containing glatiramer acetate for the treatment of multiple sclerosis
US10323289B2 (en) 2017-06-26 2019-06-18 Institut Pasteur Treatments to eliminate HIV reservoirs and reduce viral load

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL113812A (en) * 1994-05-24 2000-06-29 Yeda Res & Dev Copolymer-1 pharmaceutical compositions containing it and its use
US5719296A (en) * 1995-10-30 1998-02-17 Merck & Co., Inc. Pseudopeptide lactam inhibitors of peptide binding to MHC class II proteins

Also Published As

Publication number Publication date
EP0975351A4 (en) 2002-05-15
EP0975351A1 (en) 2000-02-02
PL193300B1 (pl) 2007-01-31
PL334566A1 (en) 2000-03-13
BR9807076B1 (pt) 2013-10-29
WO1998030227A1 (en) 1998-07-16
HUP0001917A2 (hu) 2000-10-28
CN1249690A (zh) 2000-04-05
CA2277365C (en) 2011-04-12
EA199900621A1 (ru) 2000-02-28
IL119989A0 (en) 1997-04-15
CZ297983B6 (cs) 2007-05-16
ATE356608T1 (de) 2007-04-15
AU5819598A (en) 1998-08-03
SK93199A3 (en) 2000-11-07
JP4216342B2 (ja) 2009-01-28
EP0975351B1 (en) 2007-03-14
IL130820A (en) 2007-03-08
SK284029B6 (sk) 2004-08-03
KR20000070058A (ko) 2000-11-25
HUP0001917A3 (en) 2001-12-28
CA2277365A1 (en) 1998-07-16
HK1025737A1 (en) 2000-11-24
BR9807076A (pt) 2000-05-02
BRPI9807076B8 (pt) 2021-05-25
HU226612B1 (en) 2009-04-28
DE69837324D1 (de) 2007-04-26
NZ336690A (en) 2001-05-25
CN100528222C (zh) 2009-08-19
AU737287B2 (en) 2001-08-16
ZA98214B (en) 1999-08-11
CZ243799A3 (cs) 2000-06-14
JP2001511121A (ja) 2001-08-07
EA003128B1 (ru) 2003-02-27

Similar Documents

Publication Publication Date Title
US6214791B1 (en) Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
JP4216342B2 (ja) コポリマー1の摂取又は吸入を通じての多発性硬化症の治療
DE69831971T2 (de) Unterdrückung von veränderungen in zusammenhang mit beta-amyloid bei alzheimer
Nontasut et al. Comparison of ivermectin and albendazole treatment for gnathostomiasis
DE69132688T2 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
DE3856566T2 (de) Behandlung von Autoimmun-Erkrankungen durch orale Verabreichung von Autoantigenen
WO1998030227A9 (en) Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
JP2527749B2 (ja) 移植拒否反応抑制または自己免疫疾患治療用薬学的組成物
EP2442832A1 (en) Compositions and methods for treatment of multiple sclerosis
DE69533311T2 (de) Verfahren zur behandlung von autoimmunerkrankungen mittels typ-1-interferonen
DE4413938A1 (de) Peptide als Therapeutikum für Autoimmunerkrankungen
US20240238299A1 (en) Use of pyrrolopyrimidine compound
DE69511453T2 (de) Verwendung einer Kombination von Antineoplastonen zur Herstellung eines Arzneimittels zur Behandlung der Neurofibromatose
TWI828061B (zh) 痘苗病毒致炎兔皮提取物治療神經系統脫髓鞘疾病的用途
DE60013636T2 (de) Verfahren zur behandlung endzünlicher darmerkrankungen durch verwendung von choleratoxin untereinheit b
EP4506012A1 (en) Use of extracts from rabbit skin inflamed by vaccinia virus in treatment of alzheimer's disease
Benn et al. Cryptococcal meningitis for 15 years
TR2023017347A1 (tr) Multipl Skleroz Tedavisinde Empagliflozin Kullanımı
MXPA99006457A (en) Treatment of multiple sclerosisthrough ingestion or inhalation of copolymer-1
HK1025737B (en) Treatment of multiple sclerosis through ingestion of copolymer-1
CA2264774A1 (en) Treatment of diabetes
Wiesenauer et al. New approaches to treating pollenosis—a pilot study
JP2001502696A (ja) エイズによる痴呆を処置する方法

Legal Events

Date Code Title Description
8364 No opposition during term of opposition